AGE - AgeX Therapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.4481
-0.0222 (-4.72%)
At close: 03:58PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.4703
Open0.4661
Bid0.2000 x 2200
Ask0.5775 x 1000
Day's Range0.4444 - 0.4778
52 Week Range0.3720 - 0.8400
Volume24,726
Avg. Volume20,406
Market Cap17.006M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    AgeX Therapeutics Announces Appeal of NYSE American Determination

    ALAMEDA, Calif., May 23, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on May 17, 2023 it received a notice from the staff of the NYSE American (the "Exchange") indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003(a)(i), (ii) and (iii)

  • Business Wire

    AgeX Therapeutics Reports First Quarter 2023 Financial Results

    ALAMEDA, Calif., May 12, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023.

  • Business Wire

    AgeX Therapeutics Receives Stock Exchange Deficiency Letter

    ALAMEDA, Calif., April 26, 2023--AgeX Therapeutics , Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on April 20, 2023 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Sections 1003(a)(i), (ii), and (iii) of the Exchange Company Guide in that AgeX has st

  • Business Wire

    AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results

    ALAMEDA, Calif., March 31, 2023--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.

  • Business Wire

    AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

    ALAMEDA, Calif., November 25, 2022--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of the NYSE American (the "Exchange") that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Sectio

  • Business Wire

    AgeX Therapeutics Reports Third Quarter 2022 Financial Results

    ALAMEDA, Calif., November 10, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2022.

  • Business Wire

    AgeX Therapeutics Reports Second Quarter 2022 Financial Results

    ALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.